Anti-Tachycardia Pacing and Cardioversion
- 62 Downloads
ALTHOUGH the primary focus of this text is on defibrillation issues, it is important to provide a discussion of therapies for ventricular tachycardias (VTs, that is, non-fibrillation tachyarrhythmias). In fact, tachycardia therapy is delivered much more frequently than ventricular fibrillation (VF) therapy in the general population of patients presenting with ventricular tachyarrhythmias in whom have implanted tiered therapy devices have been implanted. Patients who experience only primary ventricular fibrillation, exclusive of any tachycardia, are in the minority. The fibrillation-only patient typically experiences far fewer arrhythmia episodes than do patients with VT or supraventricular tachycardia (SVT). Although some patients present with fibrillation as the only documented or induced arrhythmia, many of these same patients had their VF episodes initiated by VT or have subsequent tachycardia episodes. About a third of the patients with ICDs implanted for cardiac arrest develop spontaneous monomorphic VTs and the vast majority are pace terminable.1
KeywordsVentricular Tachycardia Ventricular Fibrillation Cycle Length Implantable Cardioverter Defibrillator Reentrant Circuit
Unable to display preview. Download preview PDF.
- 3.Hardage ML, Sweeney MB, Automatic Tachycardia Terminating Burst Pacemakers, The Third Decade of Cardiac Pacing. Mount Kisco, New York, Futura Publishing, 1982 pp 293–307.Google Scholar
- 13.Catanzariti D, Pennisi V, Pangallo A, et al. Efficacy and safety of antitachycardia pacing in ICD patients: analysis of two-years followup. Eur JCPE 1995;5:248–252.Google Scholar
- 14.Pacifico A, Nasir N, Doyle T, et al. Safety and efficacy of antitachycardia pacing with a new third generation implantable cardioverter defibrillator, XV Congress of the European Society of Cardiology, 1993.Google Scholar